Revolutionary Aspects of Artificial Intelligence in Drug Discovery and Development
DOI:
https://doi.org/10.22270/ajprd.v14i2.1720Abstract
The pharmaceutical sector is shifting with the help of artificial intelligence (AI), which has enhanced the accuracy of drug development and discovery. AI enables predictive modeling of bioactivity and toxicity, accelerates virtual screening and lead optimization, enhances the processing of complex biological data sets, and streamlines clinical trial design and patient recruitment. To analyze how AI has transformed the pharmaceutical sector, enhanced product life cycle management, and facilitated data-informed decision-making from target candidate selection to market, this research includes high-impact studies. We also address operational, ethical, and regulatory challenges as well as what needs to be done to ensure that AI delivers its promise of creating better, faster, and cheaper cures.
Downloads
References
Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589.
Abramson J, et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature. 2024.
Pandey M, et al. The transformational role of GPU computing and deep learning in drug discovery. Nat Mach Intell. 2022;4:123–135.
Blanco-González A, et al. The role of artificial intelligence in drug discovery: challenges and opportunities. Front Pharmacol. 2023;14:1225120.
Hasselgren C, et al. Artificial intelligence for drug discovery: are we there yet? Annu Rev Pharmacol Toxicol. 2024;64:21–43.
Kim H, et al. Artificial intelligence in drug discovery: a comprehensive review. Pharmaceuticals (Basel). 2021;14:1113.
Cavasotto CN, et al. Machine learning toxicity prediction: latest advances and applications. Drug Discov Today. 2022;27:123–135.
Ferreira FJN, et al. AI-driven drug discovery: a comprehensive review. Expert Opin Drug Discov. 2025;20:45–62.
Guo W, et al. Machine learning and deep learning models for toxicity prediction. Front Pharmacol. 2023;14:1182456.
Lu X, et al. Artificial intelligence for optimizing recruitment and conduct of clinical trials. Front Med. 2024;11:1302156.
Ismail A, et al. The role of artificial intelligence in accelerating patient recruitment in clinical trials. Contemp Clin Trials. 2023;128:107164.
Qian L, et al. Enhancing clinical trial outcome prediction using machine learning. Clin Pharmacol Ther. 2025;117:345–357.
Paul SM, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9:203–214.
Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17:97–113.
Zhavoronkov A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019;37:1038–1040.
Ekins S, et al. Exploiting machine learning for end-to-end drug discovery and development. Nat Mater. 2019;18:435–441.
Vamathevan J, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18:463–477.
Stokes JM, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180:688–702.
Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24:773–780.
Exscientia. AI-designed drug discovery platform overview. Drug Discov Today. 2022;27:100–110.
Walters WP, Murcko MA. Assessing the impact of generative AI on medicinal chemistry. J Med Chem. 2020;63:865–878.
Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018;23:1241–1250.
Elton DC, et al. Deep learning for molecular design—a review of generative models. Mol Syst Des Eng. 2019;4:828–849.
Kirchmair J, et al. Predicting drug metabolism: experiment and/or computation? Nat Rev Drug Discov. 2015;14:387–404.
Rajkomar A, et al. Machine learning in medicine. N Engl J Med. 2019;380:1347–1358.
Berry DA. Bayesian adaptive clinical trials. Nat Rev Drug Discov. 2011;10:27–36.
Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25:44–56.
Harpaz R, et al. Data mining for adverse drug events. Clin Pharmacol Ther. 2012;91:1010–1021.
Ierapetritou MG, et al. Artificial intelligence in pharmaceutical manufacturing. AIChE J. 2020;66:e16861.
Bate A, Edwards IR. Data mining techniques in pharmacovigilance. Drug Saf. 2006;29:393–397.
Krittanawong C, et al. Deep learning for cardiovascular medicine. Eur Heart J. 2017;38:2059–2067.
Gawehn E, et al. Deep learning in drug discovery. Mol Inform. 2016;35:3–14.
Zitnik M, et al. Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics. 2018;34:i457–i466.
Meyers RM, et al. Computational correction of copy number effect improves CRISPR screen specificity. Nat Genet. 2017;49:1779–1784.
Pearl J. Causal inference in statistics: an overview. Stat Surv. 2009;3:96–146.
BenevolentAI. Knowledge graph applications in drug discovery. Drug Discov Today. 2021;26:200–208.
Gorgulla C, et al. An open-source drug discovery platform enables ultra-large virtual screens. Nature. 2020;580:663–668.
Atomwise Inc. AI-driven virtual screening advances. J Chem Inf Model. 2021;61:512–520.
Zhavoronkov A. Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. Mol Pharm. 2018;15:4311–4313.
Recursion Pharmaceuticals. AI-enabled phenotypic drug discovery. Nat Biotechnol. 2022;40:121–130.
Walters WP. Virtual chemical libraries and AI. J Med Chem. 2019;62:1116–1124.
Ekins S. The next era: deep learning in pharmaceutical research. Pharm Res. 2016;33:259–262.
Jiang D, et al. Could graph neural networks learn better molecular representation? J Chem Inf Model. 2021;61:2730–2740.
Hochreiter S, Schmidhuber J. Long short-term memory. Neural Comput. 1997;9:1735–1780.
Gal Y, Ghahramani Z. Dropout as Bayesian approximation. ICML. 2016.
Duvenaud D, et al. Convolutional networks on graphs for learning molecular fingerprints. NIPS. 2015.
Wu Z, et al. MoleculeNet: a benchmark for molecular machine learning. Chem Sci. 2018;9:513–530.
Sun H, et al. Deep learning-based prediction of hERG blockade. Chem Res Toxicol. 2017;30:1624–1634.
Li X, et al. AI-based toxicity screening of artemisinin derivatives. Front Pharmacol. 2022;13:1002456.
US FDA. Advancing new approach methodologies (NAMs) roadmap. 2023.
Ribeiro MT, et al. Why should I trust you? Explaining classifier predictions. KDD. 2016.
Sheridan RP. Applicability domain in QSAR modeling. J Chem Inf Model. 2013;53:283–296.
Wallach I, et al. Most ligand-based classification benchmarks reward memorization. J Chem Inf Model. 2018;58:916–932.
NIH-FDA. Modernizing toxicity testing. Science. 2022;377:990–992.
Harrer S, et al. Artificial intelligence for clinical trial design. Trends Pharmacol Sci. 2019;40:577–591.
Miotto R, et al. Deep learning for healthcare. Brief Bioinform. 2018;19:1236–1246.
He Z, et al. Clinical trial site selection using AI. J Biomed Inform. 2020;108:103487.
Franklin JM, et al. Using real-world data to create synthetic control arms. Clin Pharmacol Ther. 2021;109:118–125.
Eichler HG, et al. External control arms in clinical trials. Lancet. 2020;396:1346–1348.
Liu X, et al. Digital twin modeling in medicine. NPJ Digit Med. 2022;5:42.
Che Z, et al. Predicting patient dropout using machine learning. J Biomed Inform. 2018;85:70–78.
Acion L, et al. Machine learning in addiction recovery programs. J Subst Abuse Treat. 2017;80:59–66.
Raval AM, Bhavsar PR, Pandya FU, Patel DK. Co-processed excipients in pharmaceutical formulation: advances, characterization, and applications. Asian J Pharm Res Dev. 2026;14(1):105–113. doi:10.22270/ajprd.v14i1.1705.
Raval AM, Suthar AM, Durani B, Thakar NJ, Zankhwala FM, Kushkiwala AM, et al. Smart co-processed excipient platforms: A novel strategy for multifunctional optimization of ibuprofen tablet formulations. J Appl Bioanal. 2025;11(15 Suppl):103–128. doi:10.53555/jab.v11si15.2109.
Mevada J, Patel K, Raval A. Role of pharmacovigilance in drug safety monitoring. World J Pharm Med Res. 2025;11(11):235–240. doi:10.5281/zenodo.17482904
Mevada J, Patel K, Raval A. Materiovigilance: from device failure to safety reform, the growing importance of materiovigilance systems. Int J Pharm Sci. 2026;4(1):962–974. doi:10.5281/zenodo.18207625
Norén GN, et al. Data mining for signal detection in pharmacovigilance. Pharmacoepidemiol Drug Saf. 2008;17:133–140.
Falwariya R, Jethva T, Raval AM, Lokhande D. Comprehensive review: microneedle patches – a painless revolution in transdermal drug delivery. World J Pharm Med Res. 2026;12(1):199–207. doi:10.5281/zenodo.18085578
Topol EJ. Preparing the healthcare workforce for AI. Nat Med. 2019;25:44–56.
Wiens J, et al. Do no harm: AI for healthcare challenges. Nat Med. 2019;25:1337–1340.
Ching T, et al. Opportunities and obstacles for deep learning in biology and medicine. J R Soc Interface. 2018;15:20170387.
Rathi S, Shah S, Raval AM, Patel D, Goswami A. Physicochemical characterization and in-vitro dissolution enhancement of ranolazine using solid dispersion method. J Emerg Technol Innov Res. 2019;6(3):866–883.
Bender EM, et al. On the dangers of stochastic parrots. FAccT. 2021.
Samek W, et al. Explainable artificial intelligence: understanding, visualizing and interpreting deep learning models. IEEE Signal Process Mag. 2017;34:87–95.
Zankhwala FM, Raval AM, Kushkiwala AM, Sarvaiya SP, Raval KK, Thakar NJ, et al. Formulation and evaluation of optimized polymer blends for diclofenac diethylamine transdermal system. Rev Diabet Stud. 2025;21(S9):701–708.
EMA. Guideline on computerised systems and electronic data in clinical trials. 2023.
Viceconti M, et al. In silico clinical trials: how computer simulation will transform medicine. Sci Transl Med. 2016;8:342ps13.
Mitchell M, et al. Model cards for model reporting. FAT*. 2019.
Moor M, et al. Foundation models for biomedical AI. Nat Med. 2023;29:1318–1328.
Kairouz P, et al. Advances in federated learning. Found Trends Mach Learn. 2021;14:1–210.
US FDA. Artificial intelligence/machine learning (AI/ML)-based software as a medical device action plan. 2021.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Neetu Dharu N, Iram Fatema Siddique, Dr. Gautam B. Sonara, Dr. Manish B. Goyani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 